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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the evidence base for early palliative care interventions, including referral to specialist palliative care services for improving
outcomes in people diagnosed with a primary brain tumour and their carers.
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B A C K G R O U N D
Description of the condition
Primary brain tumours account for an estimated 2% of malignan-
cies worldwide (Ferlay 2015). Approximately 5000 people are diag-
nosed with a primary malignant brain tumour each year in the UK
(Cancer Research UK 2015). Gliomas are the most common type of
primary brain tumour, accounting for up to 80% of malignant brain
tumours overall (Goodenberger 2012). Gliomas are graded from 1
to 4 according to the World Health Organization (WHO) classifica-
tion (Louis 2016). Grades 1 and 2 are low-grade slow-growing tu-
mours. Grades 3 and 4 are high-grade fast-growing tumours. High-
grade primary malignant glioma occurs most commonly between
the fiIh and seventh decades (Stupp 2010). It is a particularly ag-
gressive disease, with a median survival time of 12 to 15 months
(Stupp 2009). The five-year survival rate is 10% (Tran 2010).
The symptom burden for people diagnosed with a high-grade
glioma is substantial. There can be profound effects on physical,
neurocognitive, and social functioning from an early stage in the ill-
ness (Faithfull 2005; Long 2016; Moore 2013). Neurological deficits
can include motor weakness, epilepsy, and dysphasia. This popu-
lation of patients also frequently experience personality changes, a
decrease in mental capacity, and mood disturbance. These effects
can be exacerbated by aggressive treatment regimens (Aziz 2003;
Long 2016).
The disease trajectory is unpredictable. It is often characterised by
periods of sudden acute deterioration followed by a period where
the clinical condition appears to plateau (Philip 2015). This makes
prognostication difficult. Patients become increasingly dependent
and isolated, which combined with the symptom burden can result
in a reduction in perceived quality of life.
Informal care providers of patients with high-grade glioma are re-
ported to experience significant burden and distress (Jacobs 2014;
Wasner 2013). Collins 2014 reported significant needs in relation
to the challenge of caring, the lack of support available to carers,
and the suffering of caregivers (Collins 2014). The neurocognitive
effects of the disease coupled with the increased dependency and
social isolation can result in changes to relationships with family
members/care providers, which are not so commonly observed in
the context of other malignancies (Ford 2012; Lipsman 2007).
Palliative care seeks to improve the quality of life of patients and
families facing a life-limiting illness through the identification, as-
sessment, and treatment of physical, psychosocial, and spiritual
needs (NCHSPCS 2002). In addition, it provides assistance with de-
cision making and supports caregiver burden and well-being. Spe-
cialist palliative care has specific areas of expertise that can ad-
dress complex symptoms, psychosocial, end-of-life, and bereave-
ment issues for patients with a life-limiting illness (NCHSPCS 2002).
Specialist palliative care teams are multi-disciplinary in nature and
specifically trained to deal with multidimensional problems, such
as those encountered in high-grade glioma.
Demonstrating the benefit of specialist palliative care in improv-
ing patient and carer-reported outcomes is an ongoing focus of
research. A systematic review by Higginson 2010 concluded that
home, hospital, and inpatient specialist palliative care teams sig-
nificantly improved patient outcomes in the domains of pain and
symptom control, anxiety, and reduced hospital admissions for
cancer patients. There is a need to better understand the effects
of different models of palliative care. Initiatives, such as the Euro-
pean-funded collaborative PRISMA, have focused on establishing
standardised outcome measures for palliative care to improve the
quality of research in this field (Harding 2010).
Previous studies have highlighted the lack of existing evidence sur-
rounding the services needed to support this patient cohort and
their care providers (Ford 2012; Moore 2013). The timing of such in-
terventions has also not been well-defined. The National Institute
for Health and Clinical Excellence (NICE) recommends that patients
with a primary brain tumour could benefit from specialist pallia-
tive and supportive care early in the process, at diagnosis if possi-
ble, with continued integration of services throughout the course of
the patient's illness (NICE 2018). However, the provision of pallia-
tive and supportive care for this patient population has historical-
ly been ill-defined and ad hoc (Faithfull 2005; Moore 2013), and the
nature of the interventions that are most beneficial has not been
confirmed.
Description of the intervention
The emphasis of palliative care is on dealing with the whole per-
son: identifying and managing physical, psychological, and spiritu-
al symptoms that profoundly affect quality of life. It also focuses on
assistance with decision making, including advance care planning
and addressing issues of relevance to significant others in terms
of caregiver burden and well-being (Radbruch 2009; Rietjens 2017;
WHO 2018).
Palliative care interventions may be initiated individually by the on-
cologist, neurosurgeon, or primary care team; by members of the
wider supportive care team in a coordinated care approach; or be
provided by specialist palliative care teams as part of an integrat-
ed model. A specialist palliative care service is defined as one deliv-
ered by a multi-professional team, usually comprising of doctors,
nurses, and psychosocial workers with higher training in palliative
care provision, possibly commissioned to provide palliative care at
a specialist level.
The concept of ‘early’ palliative care has been introduced more re-
cently to differentiate palliative interventions delivered earlier in
the disease trajectory from those in the terminal phase or last days
of life. There is, however, no universally accepted definition, with
significant heterogeneity in description of what constitutes ‘early’
in reported studies in cancer and in other serious illnesses. This
has ranged from definitions based on time since diagnosis or recur-
rence (Bakitas 2015), likely prognosis (Zimmermann 2014), in tan-
dem with oncological review (Temel 2010), or based on symptom
burden (Groenvold 2017). The American Society of Clinical Oncolo-
gy practice guidelines suggest a definition of as early as "within 8
weeks of diagnosis" (Ferrell 2016).
This Cochrane Review will focus on palliative care interventions ei-
ther in the form of a specialist palliative care service or interven-
tions undertaken by other healthcare professionals with the spe-
cific intent of palliation. The review will include interventions de-
livered to both the person with the brain tumour and the carer or
either alone. It will include interventions delivered in both commu-
nity and secondary care settings. The timing, nature, and duration
of the intervention must be clearly stipulated. Studies included in
this review will include an explicit intent to provide ‘early palliative
care’ or provide a clear study definition of ‘early’ in relation to time
Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
since diagnosis or provision during ongoing active anticancer inter-
vention.
How the intervention might work
People diagnosed with a primary brain tumour often experience
significant disability early on in their illness. A wide range of phys-
ical symptoms have been reported in existing literature including
fatigue, pain, seizures, and cognitive impairment (Armstrong 2016;
Faithfull 2005; Ford 2012). Depression and anxiety are also com-
mon. A longitudinal study of 600 patients by Batchelor 2006 identi-
fied that 15% of people with a malignant glioma had depression in
the early postoperative period and a further 93% described depres-
sive symptoms. A systematic review by Ford 2012 reported preva-
lence rates of depression and anxiety in up to 48% of people diag-
nosed with a primary malignant brain tumour.
A recent systematic review by Moore 2013 reviewed qualitative lit-
erature looking at the palliative and supportive care needs of peo-
ple with high-grade glioma and their care providers. Key themes
identified included: the need for consistent, well-delivered infor-
mation around disease sequelae, treatment, and resources avail-
able; health service needs including key professionals to coordi-
nate care; the need for psychological and social support and clear
avenues of communication with treating professionals. Vierhout
2017 conducted a qualitative study that explored the views of peo-
ple diagnosed with a brain tumour on palliative care. A key theme
identified was that people were keen to be aware of palliative care
options early in their illness.
In the wider literature there is increasing evidence that palliative
care interventions are associated with improved patient outcomes
in both malignant and non-malignant life-limiting conditions (Bak-
itas 2015; Harding 2010; Higginson 2010; Kristjanson 2006; Temel
2010; Temel 2017; Zimmermann 2014), although not all studies
demonstrate benefit (Davis 2015; Groenvold 2017). The system-
atic review by Davis 2015 highlighted significant heterogeneity
in patient populations, intervention types, settings, and outcome
measurements making comparisons difficult. Nonetheless, a re-
cent random-effects meta-analysis of palliative care interventions
on patient and carer outcomes by Kavalieratos 2016 included 43
studies across a range of conditions and demonstrated improve-
ments in patient quality of life and symptom burden. A more recent
Cochrane Review compared early palliative care interventions with
more standard treatment care in advanced cancer (but not specifi-
cally brain cancer) and again observed a significant improvement in
quality of life and symptom burden in patients receiving care short-
ly after diagnosis compared to closer to end of life (Haun 2017). An
unexpected finding in some studies has been the presence of a sur-
vival advantage in those receiving early palliative care intervention
(Bakitas 2015; Temel 2010). Although this has not been replicated
in the Kavalieratos 2016 or Haun 2017 reviews, the importance of
assessing for survival, and exploration of potential underlying rea-
sons, has been highlighted.
Why it is important to do this review
People diagnosed with a primary brain tumour experience a high
symptom burden, uncertain prognosis, and unpredictable dis-
ease trajectory. This is often characterised by rapid physical and
neurocognitive decline that can place significant burden on care
providers. Specialist palliative care services are well-placed to be
able to support the complex needs of this patient population. How-
ever there are currently no systematic reviews that have looked
specifically at the evidence base for early referral to specialist pal-
liative care services or other designated early palliative care inter-
ventions for improving quality of life, carer outcome, and overall
survival in patients diagnosed with a primary brain tumour.
Previous studies that have looked at the supportive and palliative
care needs of patients diagnosed with a high-grade glioma have
consistently concluded that the quality of evidence remains lim-
ited (Catt 2008; Collins 2014; Lin 2012; Moore 2013). In particular,
there has been a lack of studies conducted in a palliative care set-
ting. There is low-quality evidence to support multidisciplinary re-
habilitation in reducing short- and long-term disability in patients
with brain tumours compared to best supportive care (Khan 2015).
Collins 2014 concluded that carers of patients with primary ma-
lignant glioma have distinct supportive and palliative care needs
which differ from those of other cancer trajectories, although the
existing literature has yet to define how these needs might be best
addressed, by whom and at what point in a patient's care (Mc-
Conigley 2012). Defining the nature of effective interventions in this
context will help develop a more collaborative, needs-based model
of care.
The importance of this topic is recognised at a national level. The
National Institute for Health and Clinical Excellence (NICE) recom-
mends that people with brain tumours could benefit from special-
ist palliative and supportive care early in the process, at diagnosis
if possible with continued integration throughout the course of the
person's illness (NICE 2006). NICE also recommend the co-opera-
tion of neuro-oncology and specialist palliative care to “ensure an
appropriate balance between treatment and palliative care” (NICE
2006 p.121). Through doing so, NICE anticipates that not only will
communication be improved, but service provision will be more re-
sponsive to patients’ needs with more timely transfer of patients
from services and treatments, patients, and their families/care-
givers will be more satisfied and patients may be able to stay in their
preferred place of care through improved continuity of care. The
recent James Lind Alliance Neuro-Oncology Priority Setting Part-
nership Report gives context to the priority of research in this area
(MacDonald 2015).
Ultimately, understanding the role early referral to specialist pal-
liative care services or effectiveness, or both of other palliative care
interventions has on the parameters outlined would help guide
improvement to service provision and the development of an ev-
idence-based model of supportive and palliative care for this pa-
tient population.
O B J E C T I V E S
To assess the evidence base for early palliative care interventions,
including referral to specialist palliative care services for improv-
ing outcomes in people diagnosed with a primary brain tumour and
their carers.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials and non-randomised
intervention studies. We will also include qualitative studies and
mixed-methods studies where both qualitative and quantitative
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data is included. Non-randomised trials are susceptible to greater
risk of bias so to ensure an acceptable quality of included non-ran-
domised studies, we will scrutinise risk of bias using the ROBINS-I
tool (Sterne 2016), specifically designed for this purpose.
Types of participants
Inclusion criteria
• Adults (aged 18 years and older) who have a confirmed radio-
logical or histological diagnosis, or both, of a primary malignant
brain tumour.
• Informal adult carers of people with a confirmed diagnosis of a
primary malignant brain tumour. This will usually be at an indi-
vidual level but we will also include family level.
Exclusion criteria
• Participants who have a diagnosis of a benign brain tumour.
• Participants who have metastatic disease from an extra cranial
primary.
Types of interventions
We will include studies where there is explicit intent to provide ‘ear-
ly palliative care' or where there is a clear study definition of ‘ear-
ly' in relation to time since diagnosis or ongoing active anticancer
intervention. We will include studies reporting specialist and non-
specialist palliative care intervention defined as any intervention
by a healthcare professional that addresses palliation in any or all
of the following areas:
• Symptom control.
• Physical function.
• Cognitive function.
• Psychological support.
• Information giving.
• Advance or future care planning.
A specialist palliative care service is defined as one delivered by
member(s) of a multi-professional team with higher training in pal-
liative care provision, or commissioned to provide palliative care at
a specialist level, or both.
We will include interventions delivered in community and sec-
ondary care settings, and interventions delivered to both partici-
pant and carer or either alone. We will only include interventions
where the specific components of an intervention are described
and the timing (commencement) and duration of the intervention
are clearly stipulated.
The comparators of interest will be usual care, including as part of a
waiting list control. Usual care is defined as that normally provided
by the neuro-oncology team. It might include provision of general-
ist or specialist palliative care support but not intentionally activat-
ed for all people at the time of diagnosis or initiation of anticancer
treatment.
Types of outcome measures
We will include trials looking at early referral to specialist pallia-
tive care services, or early targeted palliative interventions by oth-
er healthcare professionals for improving quality of life, symptom
control, carer outcomes, or overall disease survival as a primary or
secondary outcome measure.
Primary outcomes
The primary outcomes will be quality of life, symptom control, psy-
chological outcomes, and overall survival. We will report outcomes
separately for participants and, where appropriate, carers in ‘Sum-
mary of findings’ tables using GRADEpro software (GRADEpro GDT
2014). Further details on the outcome measures that we will accept,
where reported by included studies, are shown below.
Participants
• Survival from time of enrolment, to include one year and overall
survival.
• Quality of life using validated Quality of Life tools e.g. FACT-
G (Cella 1993) and FACT- Br (Weitzner 1995), EORTC QLQ C30
and BCM 20 (Osoba 1996), McGill Quality of Life Questionnaire
(Cohen 1995), 36-Item Short Form Health Survey (SF-36) (Ware
1992), 46-item Functional Assessment of Chronic Illness Thera-
py– Palliative Care (FACIT-Pal) (Lyons 2009); qualitative analysis
of participant experience using validated and clearly described
methodologies.
• Symptom control using validated symptom assessment tools
e.g. Edmonton Symptom Assessment Scale (ESAS) (Bruera
1991); Palliative Outcomes Scale (POS) (Hearn 1999); Quality of
Life at the End of Life (QUAL-E) (Steinhauser 2004); Symptom
Experience Scale (SES) (Samarel 1996); physical and cognitive
function using validated assessment tools.
• Psychological outcomes including anxiety and depression us-
ing validated assessment tools e.g. Beck Depression Inventory
(BDI) (Beck 1961), Hamilton Rating Scale for Depression (HAM-D)
(Hamilton 1960), Hospital Anxiety and Depression Scale (HADS)
(Zigmond 1983).
Informal carer(s)
• Psychological outcomes including anxiety and depression us-
ing validated assessment tools (as mentioned above; carer bur-
den using validated assessment tools e.g. Caregiver Strain Index
(CSI) (Robinson 1983), Supportive Care Needs Survey for Part-
ners & Caregivers (SCNS-P&C) (Girgis 2011), the Carer Experi-
ence scale (CES) (Al-Janabi 2008), Quality of Life During Serious
Illness-Family Carers (QOLLTI-F) (Cohen 2006), Zarit Burden In-
ventory (Seng 2010), and FAMCARE (Kristjanson 1993)).
Secondary outcomes
The secondary outcomes will be: care coordination and informa-
tion giving by participants and carers, receipt of planned anticancer
treatment for participants, bereavement outcomes for informal
carers, carer experience, and resource use and costs. Further de-
tails on the outcome measures that we will accept, where reported
by included studies, are shown below.
Participants
• Care coordination and information giving based on qualitative
assessment of participant feedback, or objective measures of
satisfaction, or both.
• Receipt of planned anticancer treatment: completion of initial
neuro-oncology multidisciplinary team (MDT) treatment.
Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
4
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• Resource use to include hospital and hospice utilisation mea-
sured in length of inpatient stay in days, number of outpatient
appointments.
Informal carer(s)
• Care coordination and information giving based on qualitative
assessment or carer feedback or objective measures of satisfac-
tion, or both.
• Qualitative analysis of carer experience using clearly described
and validated methodologies.
• Bereavement outcomes using validated measures.
• Resource use and costs. To include opportune costs of loss of
income.
Important information on participants and carer experience of in-
terventions may be published as part of a controlled trial or sepa-
rately.
We will report outcomes separately for participants and carers in
‘Summary of findings' tables (Appendix 1; Appendix 2).
Search methods for identification of studies
Electronic searches
We will identify relevant studies by conducting searches of elec-
tronic databases, and will include the Cochrane Central Register of
Controlled Trials (CENTRAL: latest issue), MEDLINE via Ovid (1946
to present), Embase via Ovid (1980 to present), Cumulative Index to
Nursing and Allied Health Literature (CINAHL from 1982 to present),
Web of Science, and PsychInfo. We will conduct searches to incor-
porate both qualitative and quantitative search terms.
We will search for any currently recruiting trials in ClinicalTrial-
s.gov (http://clinicaltrials.gov/) and in the World Health Organiza-
tion (WHO) International Clinical Trials Registry Platform (ICTRP)
search portal (http://apps.who.int/trialsearch/).
The detailed search strategy for Ovid MEDLINE is shown in Appen-
dix 3. For databases other than MEDLINE we will adapt the search
strategy accordingly.
Searching other resources
We will handsearch the reference lists of any included articles to
identify any other relevant studies. Experts in the field will be con-
tacted to suggest relevant unidentified studies (published or un-
published). In addition we will find all included articles using cita-
tion tracking via Scopus.
We will handsearch the most relevant journals. In addition, we will
source Dissertations and Theses, searching key authors via Web of
Science and search SIGLE – System for information on grey litera-
ture in Europe.
Data collection and analysis
Selection of studies
Two review authors (ATB, AB) will independently screen and short-
list all abstracts and study titles identified by the search strategy to
assess eligibility against the inclusion criteria. We will obtain full-
text copies of all papers considered to be potentially eligible for fur-
ther assessment to determine if the study met the inclusion/exclu-
sion criteria. A second review author will then check identified pa-
pers (divided between AB, MB, FM, HB, AN, or SS). We will resolve
any disagreement by discussion with a third review author if neces-
sary (from AB, MB, FM, HB, AN, or SS) to reach a consensus. If nec-
essary, we will contact the authors of primary papers for clarifica-
tion. The review authors will not be masked to the name(s) of the
author(s), institution(s), or publication source at any level of the re-
view. We will illustrate the study selection process in a PRISMA di-
agram.
Data extraction and management
Two review authors (from ATB, AB, MB, FM, HB, AN, or SS) will inde-
pendently complete the data extraction using a standardised data
collection form and a third review author (from ATB, AB, MB, FM,
HB, AN, or SS) will independently check the data to minimise errors
and reduce potential bias. We will initially complete data extrac-
tion forms electronically for ease of distribution between review
authors. In cases where we use a paper copy, one review author
(ATB) will type up the extracted data verbatim. We will pilot the da-
ta collection forms against the checklist provided in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
and all review authors will agree the included items. Extracted da-
ta will include but not be limited to participants (including sample
size), study design, setting, intervention details, outcomes, results,
and information to facilitate the assessment of the risk of bias (i.e.
sequence generation, allocation sequence concealment, blinding).
For multiple reports of the same study, we will collate data into a
single collection form. For any data that is missing and cannot be
included in the form, we will attempt to obtain by contacting the
primary authors.
For all studies that meet the inclusion criteria, we will summarise
in the ‘Characteristics of included studies’ table provided in Review
Manager 5 software (Review Manager 2014) . This will include de-
tails on design, participants, interventions, and outcomes. For non-
randomised studies, we will provide appropriate additional study
features in line with the Cochrane Handbook for Systematic Reviews
of Interventions (Reeves 2011), such as any comparisons included,
how groups were created, and which aspects of the study were
prospective.
Assessment of risk of bias in included studies
Two review authors (from ATB, AB, MB, FM, HB, AN, or SS) will in-
dependently assess the risk of bias using the criteria and guide-
lines from the ‘Risk of bias' tool described in the Cochrane Hand-
book for Systematic Reviews of Interventions (Shuster 2011), which
a third review author (ATB, AB, MB, FM, HB, AN, or SS) will inde-
pendently check. We will report the following seven domains: allo-
cation concealment (checking if allocation methods could be fore-
seen); sequence generation (checking method of generating allo-
cation sequence); blinding (participants and personnel i.e. meth-
ods to blind participants’ knowledge of which intervention given);
blinding (outcome assessment i.e. blinding assessors from which
intervention given to the participant); incomplete outcome data
(checking differences between intervention and control groups);
selective outcome reporting (checking how outcomes are report-
ed); and ‘other bias' (including recruitment bias, stopping early for
benefit, carry-over effects in cross-over studies, and non-validated
outcome measures).
We will give each domain a judgement of risk of ‘low risk’, ‘high
risk’, or ‘unclear risk’ if insufficient details are provided in the study.
This will be accompanied with a ‘Support for judgement’ statement
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summarising how we made risk judgements to ensure transparen-
cy of the decisions made. We will consider studies to be of high
methodological quality if the risk of bias for all domains is low. We
will deem these ‘high-quality' studies. We will consider studies to
be of low methodological quality if the risk of bias is high or ‘un-
clear' one or more domains. We will deem these ‘low-quality' stud-
ies. We will resolve any disagreement on the judgement of bias by
discussions between the review authors.
For non-randomised studies, we will use the Cochrane Handbook
for Systematic Reviews of Interventions for guidance for the types
of biases these types of studies are susceptible to which are simi-
lar to randomised trials i.e. blinding (outcomes) and for biases that
cannot be compared with those randomised studies i.e. allocation
methods. We will assess risk of bias using the ROBINS-l tool (Sterne
2016), designed specifically for a non-randomised design.
Measures of treatment e8ect
We will enter and analyse all of the quantitative data in Review Man-
ager 5 (Review Manager 2014). Where possible we will calculate risk
ratios (RRs) with 95% confidence intervals (CIs) for dichotomous
data, and mean differences or standardised mean differences with
95% CIs for continuous data where different scales are used across
trials. For time-to-event data for survival, we will analyse as death
hazard ratios under the assumption that the hazard ratio is con-
sistent across the follow-up period. Where data aggregation is not
possible, we will present the results of individual studies in table
format and describe the primary findings narratively.
Unit of analysis issues
We anticipate that the appropriate unit of analysis will be by type,
timing, and duration of specialist palliative intervention for improv-
ing quality of life, carer outcomes, and survival in people diagnosed
with a primary brain tumour. We anticipate a limited number of ran-
domised controlled trials and non-randomised intervention stud-
ies.
Dealing with missing data
Where data is missing, we will contact the primary study authors in
an attempt to obtain this data. Where data is missing and cannot
be derived by contacting the primary authors, we will undertake a
complete case analysis. If the data remains missing, we will report
the study but not include it in the final analysis.
Assessment of heterogeneity
We will follow the statistical analysis method as described in the
Cochrane Handbook for Systematic Reviews of Interventions (Shus-
ter 2011). We expect heterogeneity due to differences in participant
populations, types and timing of interventions, and differences in
outcome scales used. We will assess for the presence of variation
in effects observed across studies using a Chi2 test. To quantify the
degree of heterogeneity we will employ the I2 statistic, which re-
flects the percentage of variability in effect estimates that is due to
heterogeneity rather than to chance (Deeks 2011). We will consider
a 0% to 40% threshold to be a low level of heterogeneity, 30% to
60% to be a moderate level of heterogeneity, and 50% to 90% to be
a substantial level of heterogeneity as suggested by the Cochrane
Handbook for Systematic Reviews of Interventions (Deeks 2011). We
will also describe, where possible, the potential sources of hetero-
geneity rather than simply quantify its existence. Non-randomised
studies would be expected to be more heterogeneous compared to
randomised trials and the most effective method of observing vari-
ation is through the visual inspection of the forest plots.
Assessment of reporting biases
We will aim to minimise publication bias by sourcing unpublished
data where possible. If we identify an individual meta-analysis con-
taining at least 10 studies, we will assess publication bias using fun-
nel plots and by Egger’s test (Egger 1998).
Data synthesis
We will conduct preliminary synthesis by entering all data into Re-
view Manager 5 (Review Manager 2014). The included studies will
be summarised using the ‘Characteristics of included studies' ta-
ble provided by the Review Manager 5 software. Where there is sub-
stantial and unexplained heterogeneity (P < 0.10), we will consider
pooling data using the random-effects model.
Where studies compare more than one intervention or a combina-
tion of interventions, we will analyse each comparison separately.
If possible we will calculate a weighted treatment effect using Re-
view Manager 5 software. We will express the results as risk ratios
with 95% CIs for dichotomous outcomes and mean differences and
95% CIs for continuous outcomes.
We will describe the qualitative data alongside the quantitative da-
ta and where appropriate correlate findings for example in terms of
possible domains of impact, and explorations of heterogeneity.
Summary of findings for assessing the certainty of the evidence
We will present the overall certainty of the evidence for each out-
come according to the GRADE approach, which takes into account
issues not only related to internal validity (risk of bias, inconsis-
tency, imprecision, publication bias) but also to external validity,
such as directness of results (Langendam 2013; Schünemann 2011).
We will use the GRADE approach to assess the certainty of the evi-
dence related to each of the key outcome measures listed in Chap-
ter 12.2 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Shuster 2011). We will create ‘Summary of findings' tables
using GRADEpro GDT software (GRADEpro GDT 2014; see Appen-
dix 1 and Appendix 2). We will use the GRADE checklist and GRADE
Working Group certainty of evidence definitions (Meader 2014). We
will downgrade the evidence from ‘high' certainty by one level for
serious (or by two for very serious) concerns for each limitation:
• High-certainty: we are very confident that the true effect lies
close to that of the estimate of the effect.
• Moderate-certainty: we are moderately confident in the effect
estimate. The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially differ-
ent.
• Low-certainty: our confidence in the effect estimate is limited.
The true effect may be substantially different from the estimate
of the effect.
• Very low-certainty: we have very little confidence in the effect
estimate. The true effect is likely to be substantially different
from the estimate of effect
Subgroup analysis and investigation of heterogeneity
Where sufficient studies and data exist, we will undertake the fol-
lowing subgroup analyses.
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• Tumour type.
• Age group (18 to 70 years and over 70 years).
• Type of intervention (individual vs group), frequency of interven-
tion (less than once a week, once a week, 2 to 3 times a week),
and duration of specialist palliative care intervention.
• Time from definitive treatment (surgery, radiotherapy, or
chemotherapy) to specialist palliative care intervention.
• Type of treatment received; surgery and adjuvant chemothera-
py or radiotherapy, or both; surgery alone; chemotherapy alone;
radiotherapy alone; combined chemotherapy and radiotherapy
with no surgery.
We will investigate whether the results of subgroups are significant-
ly different by performing the test for subgroup differences avail-
able in Review Manager 5 (Review Manager 2014).
Sensitivity analysis
If we identify heterogeneity across the included studies, we will un-
dertake sensitivity analyses to determine the effect of excluding
studies at high risk of bias. In addition we will use sensitivity analy-
ses to explore the effect of the primary aims of the study (early re-
ferral to specialist palliative care to improve quality of life, carer
outcomes, and overall survival for people diagnosed with a prima-
ry brain tumour).
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Appendix 1. DraF ‘Summary of findings' table for participants
 
Title: Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers
Participant or population: adults (18 years and older) with confirmed or historical diagnosis of a primary brain tumour, or both
Settings: community and secondary care settings
Intervention: early specialist or general palliative care
Comparison: usual care and waiting list control
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Illustrative compara-
tive risks*
Outcomes
Assumed
risk
Corre-
sponding
risk
Relative
effect
(95% CI)
No of par-
ticipants
(studies)
Quality of
evidence
(GRADE)
Comment
1. Survival from time of enrolment, to include one
year and overall survival.
           
2. Quality of Life using validated Quality of Life
tools;qualitative analysis of participant experience
using validated and clearly described methodolo-
gies.
           
3. Symptom burden using validated symptom as-
sessment tools;physical and cognitive function us-
ing validated assessment tools.
           
4. Psychological outcomes including anxiety and
depression using validated assessment tools.
           
5. Care coordination and information giving based
on qualitative assessment of participant feedback
and/or objective measures of satisfaction.
           
6. Receipt of planned anticancer treatment: com-
pletion of initial neuro-oncology MDT treatment
plan.
           
7. Resource use to include hospital and hospice
utilisation measured in length of inpatient stay in
days, number of outpatient appointments.
           
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Abbreviations: CI: confidence interval; HR: hazard ratio; MD: mean difference; RR: risk ratio; OR: odds ratio
GRADE Working Group grades of evidence
High-certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the
effect.
Very low-certainty: we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the
estimate of effect
  (Continued)
 
Appendix 2. DraF ‘Summary of findings' table for carers
 
Title: Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers
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Participant or population: informal adult carers of people with a confirmed diagnosis of a primary brain tumour: individual and fami-
ly level
Settings: community and secondary care settings
Intervention: early specialist or general palliative care
Comparison: usual care and waiting list control
Illustrative compara-
tive risks*
Outcomes
Assumed
risk
Corre-
sponding
risk
Relative
effect
(95% CI)
No of partic-
ipants (stud-
ies)
Quality of
evidence
(GRADE)
Comment
1. Psychological outcomes including anxi-
ety and depression using validated assess-
ment tools
           
2. Care coordination and information giv-
ing based on qualitative assessment of car-
er feedback or objective measures of satis-
faction, or both
           
3. Qualitative analysis of carer experi-
ence using clearly described and validated
methodologies
           
4. Bereavement outcomes using validated
measures
           
5. Resource use and costs including oppor-
tune costs of loss of income
           
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Abbreviations: CI: confidence interval; HR: hazard ratio; MD: mean difference; RR: risk ratio; OR: odds ratio.
GRADE Working Group grades of evidence
High-certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the
effect.
Very low-certainty: we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the
estimate of effect.
  (Continued)
 
Appendix 3. MEDLINE search strategy
Ovid MEDLINE
1. exp Palliative Care/
2. exp Terminal Care/
3. exp Terminally Ill/
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4. exp Hospices/
5. exp Hospice Care/
6. exp "Hospice and Palliative Care Nursing"/
7. ("last year of life" or LYOL or "life's end").ti,ab.
8. ((macmillan or marie curie or district) adj nurs*).mp.
9. (hospice* or (nursing adj3 home*)).mp.
10. exp Palliative Medicine/
11. exp Advance Care Planning/
12. (advance* adj5 care plan*).ti,ab.
13. (future adj5 care plan*).ti,ab.
14. exp Caregivers/
15. ((early or specialist or general or primary) adj5 palliat*).ti,ab.
16. (support* adj3 care).ti,ab.
17. palliat*.tw.
18. "advanced disease*".tw.
19. ("end-stage disease*" or "end stage disease* or end-stage illness" or "end stage").tw.
20. (end adj6 life).tw.
21. (terminal* adj6 (disease* or ill* or care*)).ti,ab.
22. ("terminal-stage*" or dying).ti,ab.
23. (close adj6 death).tw.
24. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. ((home* or in-home* or domicile or outreach or residential or housing or posthospital or post-hospital or communit* or moblie or
ambulatory or door to door) adj2 (team* or centre* or center* or treat* or care or interven* or therap* or manag* or model* or program*
or service* or nurs* or support or plan or assist*)).ti,ab.
26. (self adj3 (help* or care)).ti,ab.
27. ((psycholog* or pharmacolog* or psychiat* or social* or emotion* or spiritual* or relig* or faith or bereavement or grief or complement*
or alternative) adj3 (car* or service* or plan* or interven* or support* or assist* or prog*)).ti,ab.
28. (symptom* adj3 (care or manag* or support* or modif* or control* or assess*)).ti,ab.
29. 25 or 26 or 27 or 28
30. exp Brain Neoplasms/
31. exp Glioma/
32. (brain adj3 (tumor* or tumour* or neoplas* or malignan* or cancer* or carcinoma*)).ti,ab.
33. (glioma* or astrocytoma* or meningioma* or oligodendroglioma* or oligoastrocytoma* or glioblastoma* or GBM* or Glioblastoma
multiforme or "Primary brain tumo?r*").ti,ab.
34. 30 or 31 or 32 or 33
35. (early or advance* or forward or simultaneous).ti,ab.
36. 24 or 29
37. 35 and 36
38. 34 and 37
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